Based on our observation of ILC increase in the breast cancer models and the role of tumor ILC2 in invigorating anti-PD-1 treatment of aggressive cold pancreatic (PDAC) model (22), it seems that these cells could be valuable targets for enhancing other treatments, especially in immune deficiency cancers like breast cancer. The gene discussed is CCL27; the disease is breast cancer.